Key result
Short-term hospital thromboprophylaxis linked to a ~4.5% DVT incidence after major abdominal cancer surgery.
Why the study?
The outcomes of short-term pharmacological thromboprophylaxis after major abdominal surgery for colorectal and gastric cancer were not well evaluated.
Cohort (n=89)
No
Short-term pharmacological thromboprophylaxis during the hospital stay for major abdominal cancer surgery is associated with low rates of symptomatic DVT, though patients with coronary artery disease may require closer postoperative surveillance.
Supports short-term prophylaxis consideration after cancer surgery; leaves open optimal duration and CAD-specific monitoring needs.
PURPOSE: The aim of this study is to evaluate the outcomes of pharmacological thromboprophylaxis given for short-term duration to the patients who underwent major abdominal surgery for colorectal and gastric cancer. MATERIALS AND METHODS: This retrospective cohort study was performed in consecutive patients who underwent major abdominal surgery for colorectal and gastric cancer and received short-term pharmacological thromboprophylaxis during hospital stay were enrolled. Complete duplex ultrasonography of the lower limbs was performed for all patients to investigate both symptomatic and asymptomatic deep vein thrombosis (DVT). RESULTS: Overall, 278 patients were evaluated for inclusion and 62 colorectal and 27 gastric cancer patients were enrolled. Of 89 patients, the incidence of total and symptomatic DVT was 4.5% and 2.2%, respectively. The patients with symptomatic DVT were diagnosed within the first four months. The incidence of coronary artery disease, mucinous adenocarcinoma and vascular tumor invasion were significantly higher in patients with DVT (P-values<0.001, 0.009, and 0.02, respectively). CONCLUSION: Short-term pharmacological thromboprophylaxis after major abdominal surgery for colorectal and gastric cancer does not increase symptomatic DVT rates of patients with low Caprini score. Postoperative DVT surveillance may benefit patients with coronary artery disease, mucinous adenocarcinoma or vascular invasion of the tumor.
No takes yet. Share an insight, caveat, or question.
Çolapkulu et al. (2021) conducted a cohort in Colorectal and gastric cancer (n=89). Short-term pharmacological thromboprophylaxis (enoxaparin) was evaluated on Incidence of total deep vein thrombosis (DVT). Short-term pharmacological thromboprophylaxis during the hospital stay after major abdominal surgery for colorectal and gastric cancer was associated with an overall deep vein thrombosis incidence of 4.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: